![]() |
市場調查報告書
商品編碼
1709426
印度的靜脈通路裝置市場:各產品類型,各用途,各終端用戶,各地區,機會,預測,2019年~2033年India Vascular Access Devices Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, FY2019-FY2033F |
印度血管通路設備市場規模預計將從 2025 年的 4.7993 億美元增長到 2033 年的 7.6107 億美元,預測期內(2026-2033 年)的複合年增長率為 6.81%。由於糖尿病和癌症等需要長期血管通路治療的生活方式相關疾病的增加,印度血管通路設備市場正在經歷顯著增長。政府對醫院基礎設施的投資和醫療服務的改善正在加速這些設備的採用。此外,導管材料和設計的創新正在提高安全性、效率和病患治療效果,促進其在醫療保健領域的進一步應用。
例如,雅培宣佈在印度推出其新的血管成像平台及其 Ultreon 1.0 軟體。使用人工智慧 (AI) 和光學相干斷層掃描 (OCT) 的血管內影像軟體讓醫生能夠全面了解冠狀動脈阻塞和血流。這款尖端成像軟體可以評估血管直徑,識別鈣基阻塞的程度,並自動區分鈣化和非鈣化阻塞。提高冠狀動脈支架置入的準確性,為支架置入提供精準的引導,確保支架最佳擴張和放置,並提供即時結果。
本報告提供印度的靜脈通路裝置市場相關調查,提供市場概要,以及各產品類型,各用途,各終端用戶,各地區趨勢,及加入此市場的主要企業簡介等資訊。
India vascular access devices market is projected to witness a CAGR of 6.81% during the forecast period FY2026-FY2033, growing from USD 479.93 million in FY2025 to USD 761.07 million in FY2033. India market for vascular access devices has grown significantly because of the rising prevalence of lifestyle-related diseases such as diabetes and cancer, which require long-term vascular access. Government investments in hospital infrastructure and improved access to healthcare services are accelerating device adoption. Additionally, innovation in catheter materials and design is enhancing safety, efficiency, and patient outcomes, promoting further uptake across healthcare settings.
For example, Abbott declared the introduction of their new vascular imaging platform in India, which is driven by Ultreon 1.0 software. Using artificial intelligence (AI) and optical coherence tomography (OCT), intravascular imaging software gives doctors a thorough understanding of coronary artery blockages and blood flow. The cutting-edge imaging software can assess vessel diameter, identify the degree of calcium-based blockages, and automatically distinguish between calcified and non-calcified blockages. In order to improve accuracy during coronary stenting procedures, it also assists doctors in guiding exact stent deployment, guaranteeing optimal stent expansion and apposition with instantaneous results presentation.
Growing Burden of Chronic and Infectious Diseases in India
India is witnessing a steep rise in the prevalence of chronic diseases such as cancer, chronic kidney disease, and cardiovascular ailments, along with infections requiring frequent hospitalizations. These conditions often demand long-term administration of medications, IV fluids, and blood transfusions, significantly increasing the demand for vascular access devices. Additionally, the increasing geriatric population, which is more susceptible to chronic conditions, has contributed to higher hospitalization and intravenous intervention rates. Moreover, the burden of infectious diseases like dengue and sepsis continues to require efficient diagnostic and treatment solutions, further supporting the need for secure vascular access. Government schemes such as Ayushman Bharat and expanded healthcare coverage are improving access to healthcare facilities, which in turn increases procedural volumes where vascular access devices are used. This broad healthcare push, combined with higher patient volumes and increasing disease burden, is driving consistent growth in the demand for vascular access devices across India. The burden of noncommunicable diseases (NCDs) has overtaken that of infectious diseases in India. An estimated 5.8 million Indians lose their lives to NCDs annually, and one in four Indians are at danger of passing away before turning 70. The World Health Organization (WHO) estimates that NCDs cause nine million deaths a year in Southeast Asia, or 62% of all deaths. The high rate of premature fatalities, or deaths that happen before the age of 70, associated with NCDs is a serious concern.
Rising Healthcare Infrastructure and Technological Advancements
India's healthcare infrastructure has seen massive development in recent years, with increasing numbers of public and private hospitals, specialty clinics, and diagnostic centers. These facilities are increasingly adopting advanced medical devices, including next-generation vascular access devices that offer safer insertions, longer dwell times, and improved infection control. Local manufacturing by Indian companies such as Poly Medicure and Newtech Medical Devices has led to the availability of cost-effective, technologically enhanced solutions that match global standards. Additionally, the "Make in India" initiative has catalyzed innovation and local production of vascular access devices, enhancing availability and affordability. Hospitals and surgical centers are becoming more equipped with imaging-guided insertion tools, antimicrobial-coated catheters, and closed IV systems to reduce complications. This rapid evolution in infrastructure, alongside the acceptance of new technologies in vascular access, is playing a pivotal role in strengthening the market across Tier 1 and Tier 2 cities in India. In August 2023, Poly Medicure Ltd., a major Indian vascular access device manufacturer, opened its 10th manufacturing facility in India to enhance its product offerings, including central venous catheters, PICCs, and other vascular access solutions, under the "Make in India" initiative. This expansion supports the local availability of advanced and affordable vascular access devices.
High Adoption of Central Vascular Access Devices in Critical Care
Central vascular access devices (CVADs) are witnessing increasing demand in India, especially in ICUs and oncology centers. Their ability to provide long-term venous access, administer large volumes of fluids, chemotherapeutics, and parenteral nutrition makes them critical for managing severely ill patients. In tertiary care hospitals, CVADs are preferred for hemodynamic monitoring and blood sampling in patients requiring prolonged treatment. Moreover, the rising number of organ transplants, dialysis cases, and cancer treatments are expanding their use. Central lines, such as peripherally inserted central catheters (PICCs), tunneled catheters, and implanted ports, are gaining traction due to their lower infection rates and enhanced patient comfort when used for long durations. The increasing awareness about catheter-associated bloodstream infections (CLABSIs) is also encouraging hospitals to adopt high-quality CVADs with antimicrobial coatings. This growing preference and usage in critical care and oncology settings are making central vascular access devices a key revenue-generating segment in the Indian market. In March 2024, AIIMS Delhi announced upgrades to its ICU facilities, including the adoption of new generation of antimicrobial-coated central venous catheters (CVCs) for critical care, aimed at reducing bloodstream infections. This is part of their infection control program and reflects a growing preference for central vascular access devices in tertiary and teaching hospitals.
Future Market Scenario (FY2026 - FY2033F)
The India vascular access devices market is expected to witness robust growth in the coming years, driven by increasing hospital admissions, a rising burden of chronic diseases, and expanding healthcare infrastructure. With growing awareness of infection control and a push for safer, more efficient intravenous access methods, demand for advanced vascular access technologies is projected to rise. Additionally, government initiatives to strengthen public healthcare facilities and the rise of private multispecialty hospitals are anticipated to support market expansion. Local manufacturing capabilities and technological collaborations may further enhance the domestic supply chain for these devices.
Key Players Landscape and Outlook
Key players in the vascular access devices industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, former L&T chairman AM Naik and seasoned businessman Madhusudan Kela are among the investors who have contributed approximately Rs 300 crore to S3V Vascular Technologies Limited, a medical device manufacturing company situated in Mysore.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.